In other recent news, ARS Pharmaceuticals has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for the marketing of EURneffy®, a needle-free adrenaline nasal spray for emergency treatment of severe allergic reactions. The final marketing authorization process by the European Commission is expected in the third quarter of 2024. The product, which demonstrated efficacy in a data package involving over 700 participants and more than 1,200 administrations, is anticipated to be available in Europe in the fourth quarter of 2024.